A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 12 Mar 2018 Results published in the Journal of Clinical Oncology
    • 21 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 13 Feb 2018 According to a Hutchison MediPharma media release, results from this trial were highlighted in an oral presentation at the 17th World Conference on Lung Cancer on 6 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top